Document is current
Any future updates will be listed below
-
Authors
Ura, Takashi
Hironaka, Shuichi https://orcid.org/0000-0001-9714-231X
Tsubosa, Yasuhiro
Mizusawa, Junki
Kato, Ken
Tsushima, Takahiro
Fushiki, Kunihiro
Chin, Keisho
Tomori, Akihisa
Okuno, Tatsuya
Matsushita, Hisayuki
Kojima, Takashi
Doki, Yuichiro
Kusaba, Hitoshi
Fujitani, Kazumasa
Seki, Shiko
Kitagawa, Yuko
-
Funding
Funding for this research was provided by:
National cancer research and development fund (23-A-16, 23-A-19)
National cancer center research and development fund (26-A-4, 29-A-3)
National cancer center research and development (2020-J-3)
Grants-in-Aid for Cancer Research (20S-3)
Japan Society for the Promotion of Science (20S-6)
- License Information
-
More Information
Article History
Received: 13 July 2022
Accepted: 29 October 2022
First Online: 22 November 2022
Declarations
:
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.
: Dr. Hironaka received grants from Ministry of Health, Labor and Welfare, Japan and lecture fees from Ono, BMS Japan, Daiichi Sankyo, Taiho, Lilly, Chugai, Nihonkayaku, Tsumura & Co., Sanofi, Merck, AstraZeneca, Yakult Honsha, and Takeda. Furthermore, he serves as a consultant to Ono, BMS Japan, Daiichi Sankyo. Dr. Mizusawa received grants from Ministry of Health, Labour and Welfare of Japan, lecture fees from Chugai and Taiho, and other financial or non-financial interest from Pfizer. Dr. Kato received lecture fees from BMS, Ono, Bayer, Beigene, AstraZeneca, and MSD. Dr. Chin received lecture fees from Taiho, Chugai, Ono, MSD, and BMS. Dr. Kojima received grants from Ono, BMS, BeiGene, EPS, MSD, Amgen, Shionogi, Chugai, Taiho, Parexel, and Merck and lecture fees from BMS, Ono, Covidien, MSD, Taiho, Oncolys, Merck, and Astellas. Dr. Kitagawa received grants from Takeda, Chugai, Taiho, Yakult, AsahiKasei, Otsuka, Ono, Tsumura, Kyowa Kirin, Dainippon Sumitomo, EA Pharma, Medicon, Kaken Pharma, Eisai, Otsuka Pharmaceutical Factory Inc., Teijin, Nihon Pharma, and Nippon Covidien and lecture fees from Chugai, Taiho, AsahiKasei, Otsuka, Shionogi, Nippon Covidien, Ethicon, Ono, Olympus, BMS, AstraZeneca, MSD, Smith&Nephew, Kaken Pharma, ASKA, and Miyarisan Pharma. Dr. Ura, Dr. Tsubosa, Dr. Tsushima, Dr. Fushiki, Dr. Tomori, Dr. Okuno, Dr. Matsushita, Dr. Doki, Dr. Kusaba, Dr. Fujitani, and Dr. Seki declare that they have no conflict of interest.
: Informed consent or substitute for it was obtained from all patients for being included in the study.
